Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | XBP1 | P17861 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22382283 | 0.80 | ALDH1A1 (0.52) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL14937755 | 0.79 | ALDH1A1 (0.46) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL3271257 | 0.78 | APP (0.47) | CYP2C9CYP17A1CYP2C19ALDH1A1MAPT | |
| SCHEMBL30450739 | 0.78 | CYP17A1 (0.58) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL28350845 | 0.78 | CYP17A1 (0.58) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL8148994 | 0.76 | KDM4E (0.48) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL4450625 | 0.76 | CYP2C9 (0.45) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL4408334 | 0.76 | KDM4E (0.51) | CYP2C9KDM4EALDH1A1MAPTCYP1A2 | |
| SCHEMBL4719177 | 0.76 | APP (0.50) | GPR3CYP2C9CYP17A1CYP2C19KDM4E | |
| SCHEMBL498377 | 0.75 | ALDH1A1 (0.56) | GPR3CYP2C9CYP17A1CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008008273-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | CENERX BIOPHARMA, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-7812050-B2 | Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide | CENERX BIOPHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812050-B2 | Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide | CENERX BIOPHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812050-B2 | Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide | CENERX BIOPHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2008008273-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | CENERX BIOPHARMA, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008273-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | CENERX BIOPHARMA, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20080009542-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | CENERX BIOPHARMA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009542-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | CENERX BIOPHARMA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009542-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | CENERX BIOPHARMA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009542-A1 | POLYMORPHIC FORM OF FLUORO-7-(2,2,2-TRIFLUOROETHOXY) PHENOXATHIIN-10,10-DIOXIDE | UGT1A10, CYP2F1, F10 | GPR3 2350/4885CYP2C9 11/4885CYP17A1 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.